Aurobindo Pharma arm gets USFDA nod for Plerixafor injection
Aurobindo Pharma said Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Transplants